Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Achaogen Inc    AKAO

ACHAOGEN INC (AKAO)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/11/2018 07/12/2018 07/13/2018 07/16/2018 07/17/2018 Date
8.29(c) 8.34(c) 7.82(c) 7.06(c) 7.2(c) Last
1 189 756 1 238 726 878 018 2 089 395 1 082 824 Volume
+5.61% +0.60% -6.24% -9.72% +1.98% Change
More quotes
Financials (USD)
Sales 2018 13,8 M
EBIT 2018 -164 M
Net income 2018 -165 M
Finance 2018 47,6 M
Yield 2018 -
Sales 2019 52,8 M
EBIT 2019 -131 M
Net income 2019 -138 M
Finance 2019 35,9 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 21,9x
EV / Sales2019 5,96x
Capitalization 350 M
More Financials
Company
Achaogen, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections.It offers Plazomicin to treat bacterial illness, such as complicated urinary tract infection, blood... 
More about the company
Surperformance© ratings of Achaogen Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACHAOGEN INC
07/12ACHAOGEN : to Host Investor Lunch Updating Investors on Commercial Strategy Post..
AQ
07/10Achaogen to Host Investor Lunch Updating Investors on Commercial Strategy Pos..
GL
07/02ACHAOGEN : Bill seeks to introduce 'pull' incentive for antibiotics
AQ
06/29ACHAOGEN : UPDATE-ZEMDRI Approved by FDA for the Treatment of Adults with Compli..
AQ
06/28ACHAOGEN : It`s a good news, bad news FDA approval for Achaogen`s powerful antib..
AQ
06/27ACHAOGEN : UPDATE -- ZEMDRI (plazomicin) Approved by FDA for the Treatment of Ad..
AQ
06/27TODAY’S RESEARCH REPORTS ON STOCKS T : Achaogen and Avinger
AC
06/27ACHAOGEN : Plazomicin Receives FDA Approval for Complicated UTIs
AQ
06/27ACHAOGEN : FDA approves plazomicin for cUTI, but not blood infections
AQ
06/27ACHAOGEN : ZEMDRITM (plazomicin) Approved by FDA for the Treatment of Adults wit..
AQ
More news
Sector news : Bio Therapeutic Drugs
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
02:53a$AKAO shorts keep adding, now 53% of the float -  
07/17Leerink Swann Lowers Achaogen FY2022 Earnings Estimates to $0.26 EPS (Previou.. 
07/15$AKAO Inc ... Weekly Insider Tables: July 14, 2018: InsiderInsights Ratings .. 
07/14Some of you $AKAO longs are losing your goddamn minds!! Don’t be stepping to .. 
07/13Again this is why $PRTK (possibly if data good) and $NBRV will be much better..
1
More tweets
Qtime:64
News from SeekingAlpha
07/16ACHAOGEN : Smaller Label, Unchanged Market? 
07/12ROUNDS REPORT : The July 4th Weekend Procured Substantial Profits For Investors .. 
07/11Achaogen to host lunch updating investors on commercial strategy post FDA app.. 
07/10ACHAOGEN : Zemdri To The Rescue 
07/09Midday Gainers / Losers (07/09/2018) 
Chart ACHAOGEN INC
Duration : Period :
Achaogen Inc Technical Analysis Chart | AKAO | US0044491043 | 4-Traders
Technical analysis trends ACHAOGEN INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 17,5 $
Spread / Average Target 148%
EPS Revisions
Managers
NameTitle
Blake Wise Chief Executive Officer & Director
Kenneth J. Hillan President & Director
Bryan E. Roberts Chairman
Tina M. Larson Senior Vice President-Technical Operations
Tobin Schilke Chief Financial Officer
Sector and Competitors
1st jan.Capitalization (M$)
ACHAOGEN INC-32.96%350
GILEAD SCIENCES7.84%100 614
VERTEX PHARMACEUTICALS20.45%45 997
REGENERON PHARMACEUTICALS-2.21%38 951
GENMAB5.93%10 467
NEUROCRINE BIOSCIENCES, INC.32.61%9 250